Merck adds to biopharma’s AI agenda with up to $510M+ Protillion pact (June 17, 2026) by Tristan Manalac Merck will use Protillion Biosciences’ tech to design biologic therapies for therapies across undisclosed indications. The next stop on biopharma’s AI train is Merck, which is bringing on California’s Protillion Biosciences to combine large-scale data generation and AI design to advance a

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform (June 8, 2026) by J&J Global Media Relations NEW BRUNSWICK, NJ (June 8, 2026) – Johnson & Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink™ degrader

Moderna and other groups get $60 million to develop Ebola vaccine (June 1, 2026) by By Jennifer Rigby, Mariam E Sunny and Julie Steenhuysen Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting their money behind more mature and de-risked assets. June 1 (Reuters) – Global health organisation CEPI will

AI-fueled Isomorphic bags $2.1B, the second largest biotech round ever (May 13, 2026) by Tristan Manalac Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting their money behind more mature and de-risked assets. Alphabet’s AI-forward biotech Isomorphic Labs has brought in $2.1 billion, clocking what analysts say is “the second

Kailera Plans IPO for Obesity Drug That Could Top Lilly’s Zepbound (March 30, 2026) by Frank Vinluan Kailera Therapeutics’ planned IPO will fund ongoing clinical development of a pipeline led by a drug that could rival Eli Lilly’s Zepbound in both efficacy and tolerability. Meanwhile, Renaissance Capital’s recap of first quarter 2026 IPOs shows slowing activity amid market turbulence from

Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly (March 29, 2026) by Reuters In March 2026, Eli Lilly signed a global licensing deal worth up to $2.75 billion. The partnership utilizes Insilico’s AI platform to develop novel oral therapeutics, including a preclinical GLP-1 candidate for diabetes.Eli Lilly & Insilico Medicine: A $2.75 Billion Strategic AI-Driven Partnership Pharmaceutical companies

Drug developer Generate Biomedicines raises $400 million in US IPO (February 26, 2026) by Reuters Founded by Flagship in 2018, Generate Biomedicines uses AI-driven technology to move beyond traditional trial-and-error drug discovery and develop new protein-based therapies, with its pipeline centered on immunology and oncology. Generate’s lead drug candidate for severe asthma, GB-0895, is currently in a late-stage trial, with

Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics (Ingelheim, Germany, Oxford, UK, and Boston, USA, Feb 26, 2026) by Linda Ruckel and Dr Reinhard Malin. The preclinical, small molecule program offers a potential first-in-class, oral, precision immunometabolic approach to modulating disease-driving immune cells Deal includes upfront and milestone payments to Sitryx totaling over US $500

Roche obesity drug shows 22.5% weight loss as it seeks to catch up with Lilly, Novo (Jan 27, 2026) by Reuters. BERLIN, Jan 27 (Reuters) – Roche’s experimental obesity drug, which works in a similar way to Eli Lilly’s Zepbound, produced as much as 22.5% weight loss in a mid-stage trial, underpinning the Swiss drugmaker’s efforts to catch up with

In Structure licensing deal, Roche commits $100M to shore up GLP-1 position (March 30, 2026) by Angus Liu Disclosed in January 2026, Roche paid $100 million for a nonexclusive license to patents from Structure Therapeutics. This strategic move protects Roche’s oral GLP-1 candidate, CT-996, from potential patent litigation. Read More